Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review.

RATIONALE: Management of anxiety, delirium, and agitation cannot be neglected in coronavirus disease (COVID-19). Antipsychotics are usually used for the pharmacological management of delirium, and confusion and behavioral disturbances. The concurrent use of treatments for COVID-19 and antipsychotics should consider eventual drug-drug interactions
OBJECTIVE: To systematically review evidence-based available on drug-drug interactions between COVID-19 treatments and antipsychotics. EVIDENCE REVIEW: Three databases were consulted: Lexicomp® Drug Interactions, Micromedex® Solutions Drugs Interactions, and Liverpool© Drug Interaction Group for COVID-19 therapies. To acquire more information on QT prolongation and Torsade de Pointes (TdP), the CredibleMeds® QTDrugs List was searched. The authors made a recommendation agreed to by consensus. Additionally, a systematic review of drug-drug interactions between antipsychotics and COVID-19 treatment was conducted.
RESULTS: The main interactions between COVID-19 drugs and antipsychotics are the risk of QT-prolongation and TdP, and cytochromes P450 interactions. Remdesivir, baricinitib, and anakinra can be used concomitantly with antipsychotics without risk of drug-drug interaction (except for hematological risk with clozapine and baricinitib). Favipiravir only needs caution with chlorpromazine and quetiapine. Tocilizumab is rather safe to use in combination with antipsychotics. The most demanding COVID-19 treatments for coadministration with antipsychotics are chloroquine, hydroxychloroquine, azithromycin, and lopinavir/ritonavir because of the risk of QT prolongation and TdP and cytochromes interactions. The systematic review provides highly probable drug interaction between lopinavir/ritonavir plus quetiapine and ritonavir/indinavir plus risperidone.
CONCLUSIONS: Clinicians prescribing antipsychotics should be aware of the likely risk of drug-drug interaction with COVID-19 medication and may benefit from taking into account present recommendations of use to preserve patient safety.

Introduction

The number of people affected by coronavirus disease 2019 (COVID-19) worldwide is over 32 M and rapidly increasing, and the importance of knowledge of symptom management and treatment for general practitioners and other clinicians must be stressed. Although the key symptoms are cough, fever, and breathlessness, anxiety, delirium, and agitation are also present in a large number of patients (National Institute for Health and Care Excellence (NICE) in collaboration with NHS England and NHS Improvement 2020). Up to 20–30% of COVID-19 patients will have with or develop delirium or changes in the mental health during their hospitalizations, and these numbers are as high as 60–70% in severely ill patients (Helms et al. 2020; Mao et al. 2020). The duration of delirium has consistently proven to be an independent predictor of longer hospitalization, higher mortality, and higher cost (E. Ely et al. 2001; E. W. Ely et al. 2004; Vasilevskis et al. 2018), and delirium is often inadequately managed (O’Hanlon and Inouye 2020). Antipsychotics drugs (APs) are usually selected for the pharmacological management of delirium (Kotfis et al. 2018), and confusion and behavioral disturbances associated with hospitalization of elderly patients (Jin and Liu 2019; van der Linde et al. 2014).

COVID-19 patients are being treated with chloroquine, hydroxychloroquine (Colson et al. 2020; Shukla et al. 2020), azithromycin (Gautret et al. 2020), and lopinavir/ritonavir (Cao et al. 2020), with a possible increased of QT prolongation and TdP, and other drug-drug interactions (DDIs) in coadministration with antipsychotics. The severely ill patients being treated are the most likely to suffer from QT prolongation, because of the clinical condition known to prolong QT, and the concomitant drugs, and clinicians need to mitigate that risk (Giudicessi et al. 2020). This use is complicated by age-related decline in drug metabolism (Zanger and Schwab 2013), high incidence of concomitant physical illnesses, drug-drug interactions, and heightened sensitivity to APs (Gareri et al. 2014; Maher et al. 2011; Rivière et al. 2019). In addition, COVID-19 also affects the cardiovascular system. Arrhythmia (atrial fibrillation, ventricular fibrillation, and ventricular tachyarrhythmia), cardiac injury, fulminant myocarditis, heart failure, pulmonary embolism, and disseminated intravascular coagulation are the most common cardiovascular complications in COVID-19 patients (Guzik et al. 2020); some of which are clinical factor associated with prolonged QTc and/or TdP (Woosley et al. n.d.-a).

APs are associated with a proarrhythmic state and an increased risk of sudden cardiac death (SCD), without substantial differences between first and second generation antipsychotics, and a dose-response effect (Ray et al. 2009; Salvo et al. 2016). Antipsychotics (exception aripiprazole and lurasidone) seem to be associated with a prolonged QT interval and an increased risk of SCD (Acciavatti et al. 2017). There are differences among APs in the degree of cardiotoxic effects (Leucht et al. 2013). SCD describes the unexpected natural death, from a cardiac cause within a short time, of a person who often has no prior cardiological condition that would appear fatal (Wellens et al. 2014). Many antipsychotics show a certain degree of blockade of potassium channels coded by the human ether-à-go-go-related gene (hERG), thus inducing a QT interval prolongation and increasing the risk of polymorphic ventricular tachycardia/torsade de Pointes (TdP) (Roden 2004; Testai et al. 2004). The most common acquired cause of long QT syndrome and TdP is drug-induced QT interval prolongation. Intensive care unit patients are particularly prone to experience a QTc interval prolongation mainly due to certain drugs that can prolong the repolarization phase, either by their action mechanism or through the interaction with other drugs (Etchegoyen et al. 2017) (a complete list of clinical factors associated with prolonged QTc and/or TdP can be consulted in www.QTFactors.org). Elderly patients are in particularly prone to proarrhythmic risk with antipsychotics (Vieweg et al. 2009). Also, the potential for pharmacokinetic DDIs of APs are mostly mediated by cytochrome P450 (CYP) enzymes metabolism; therefore, physicians should be aware of co-administered drugs that may inhibit or induce these CYP enzymes (Conley and Kelly 2007; Kennedy et al. 2013; King et al. 2004).

The aim of our review is to analyze the risks of DDIs and cardiovascular adverse events of antipsychotics with the main treatments currently used for COVID-19. More so, SARS-CoV-2 primarily affects the elderly with other associated cardiovascular risk factors, which often require hospitalization, and treatment of which is essential to knowing the risk and safety of antipsychotics associated with COVID-19 treatments.

Methods

Drugs currently used in the treatment of SARS-CoV-2 (Sanders et al. 2020) such as chloroquine, hydroxychloroquine, lopinavir/ritonavir, remdesivir, and tocilizumab have been reviewed and also azithromycin with promising results (Gautret et al. 2020), and potential therapeutic agents such as favipiravir (Jean et al. 2020), baricitinib (Cantini et al. 2020), and anakinra (Monteagudo et al. 2020).

Drug-drug interactions: antipsychotics and COVID19 drugs

Three databases were searched: (a) Lexicomp® Drug Interactions (Wolters Kluwer 2020), (b) Micromedex® Solutions Drugs Interactions (Truven Health Analytics. Micromedex® Solutions Drugs Interaction [Electronic Version], 2020), and (c) Liverpool© Drug Interaction Group for COVID-19 therapies (University of Liverpool. Liverpool COVID-19 Interactions, 2020). After an exhaustive review of various drugs interaction databases, the first two met the minimum quality criteria (Rodríguez-Terol et al. 2009), with good scores for scope, completeness, and ease of use (Patel and Beckett 2016). The following information was extracted (when available): type of interaction, risk rating, and severity (both, according to the stratification in each database) and patient management recommendations.

QT prolongation and TdP risk

To find out more about QT prolongation and TdP, the CredibleMeds® QTDrugs List (Woosley et al. 2020) was searched. CredibleMeds® classifies drugs based on their risk of QT prolongation or TdP—risk category: (a) Known Risk of TdP, (b) Possible Risk of TdP, (c) Conditional Risk of TdP.

Consensus recommendation

After the above information had been collected, the authors made consensus recommendations based on the following:

Not recommended (red zone), if (1) coadministration contraindicated in one or more databases, or (2) both drugs classified as “Known Risk of TdP” (risk of QT prolongation or TdP).

Recommended with caution. Two categories:

Potential interaction, which may require a dose adjustment, close monitoring, or choosing alternative agents, in two or more databases (orange zone).

Potential interaction intensity likely to be weak. Additional action/monitoring or dose adjustment unlikely to be required, in two or more databases (yellow zone).

Recommended (green zone), if little or no evidence of clinically significant interaction is expected in two or more databases.

When there were differences between databases, and it was not possible to reach an agreement by consensus, our recommendations reflect the most conservative approach.

When QT-prolongation is the main risk, we present the APs in two groups according to CredibleMeds® (“Possible” or “Conditional” risk) to increase the clinical information.

Systematic review

Additionally, a systematic review was conducted according to PRISMA guidelines (Moher et al. 2009) (registration number in PROSPERO CRD42020183202) to find clinical outcomes of drug-drug interactions between COVID-19 treatment and antipsychotics.

We researched the following databases: MEDLINE, EMBASE, and Web of Science. The search was restricted to the English language using database filters. No date restriction was imposed for the updated search. The search strategy will follow syntax: antipsychotic* AND (chloroquine OR hydroxychloroquine OR lopinavir OR ritonavir OR remdesivir OR tocilizumab OR azithromycin OR favipiravir OR baricitinib OR anakinra). The reference list of all identified articles was examined for any additional study not found in the first search.

Inclusion and exclusion criteria

Inclusion criteria which refer to the characteristics for a given study to be eligible are as follows: (1) publication reporting clinically significant drug-drug interactions (between antipsychotics and COVID-19 treatment in adult patients (whatever the disease prescribed for) and (2) types of publication: randomized controlled trial, other controlled study, observational study, case report, and case series. Exclusion criteria are as follows: (1) only pharmacokinetic studies (no clinical outcome), (2) unpublished studies or gray literature and conference articles.

Three reviewers (G.R., A.R., M.R.) independently screened titles for the research question and criteria. When articles were deemed to meet the inclusion criteria by either reviewer, the abstract was analyzed. Full texts were retrieved when the reviewers were in agreement that the article met the inclusion criteria. Disagreements were solved by a fourth independent reviewer (B.P.). Rayyan QCR was used for duplicated data and screening (Ouzzani et al. 2016).

Data extraction

Two authors reached an agreement regarding the type of data to be collected, and relevant information such as the study design, context of drug interactions, clinical outcome, other comedication data, and the numbers and types of patients was recorded.

Risk of bias and generalizability concerns in comparative studies were evaluated with an adaptation of the Newcastle-Ottawa quality assessment scale for case control and cohort studies (Stang 2010), an eight-item tool designed to rate methodological aspects of case-control and cohort studies, which include three domains: study selection, comparability of cohorts on the basis of the design or analysis, and exposure. The overall score ranges from 0 to 9. Risk of bias and generalizability concerns in case reports and case series were evaluated with the Drug Interaction Probability Scale (DIPS) tool to assess the quality of papers retained (Horn et al. 2007). This 10-question tool evaluates drug interaction causation. Scores < 2 indicate doubtful drug interaction, scores 2–4 possible, 5–8 probable, and scores ≥ 9 indicate highly probable drug interaction.

Results

The authors’ consensus recommendations are summarized in Table 1.

Table 1

Author’s recommendation summary

HCLQ hydroxychloroquine, CLQ chloroquine, AZT azithromycin, LPV/r: lopinavir/ritonavir, RDV remdesivir, FAV favipiravir, TCZ tocilizumab, BAR baricinitib, ANK anakinra

TdP Risk: Risk Categories for Drugs that prolong QT and induces Torsade de Pointes (TdP): Known Risk of TdP (these drugs prolong the WT interval and are clearly associated with a known risk of TdP, even when taken as recommended), Possible Risk of TdP (these drugs can cause QT prolongation but currently lack evidence for risk of TdP when taken as recommended), Conditional Risk of TdP (these drugs are associated with TdP but only under certain conditions of their use (e.g., excessive dose, in patients with conditions such as hypokalemia, or when taken with interacting drugs) or by creating conditions that facilitate or induce TdP (e.g., by inhibiting metabolism of QT-prolonging drugs or by causing an electrolyte disturbance that induce TdP), Not classified (this drug has been reviewed but the evidence available at this time did not result in a decision for it to be placed in any of the four QT risk categories. This is not an indication that this drug is free of a risk of QT prolongation or Torsade de Pointes since it may not have been adequately tested for these risks in patients) according to CredibleMeds®

Risk Rating: Zone Red: Not recommended, Zone Orange: Potential interaction which may require a dose adjustment, close monitoring, choosing alternative agents in 2 or more database, Zone Yellow: Potential interaction likely to be of weak intensity. Additional action/monitoring or dose adjustment unlikely to be required in 2 or more database, Zone Green: Little to no evidence of clinically significant interaction expected in 2 or more database

△The most conservative approach. There is not enough information to assign the antipsychotic to any of the previous categories. This recommendation to be taken with caution; (*) Only classified in one database but in this category

Type of interaction: ♥♥ QT-Prolonging agents in 2 or more database, ♥ QT-Prolonging agents in 1 database; ↑/↓ Potential increased/decreased exposure of APs; ⇧Potential increased exposure of COVID-19 treatment; § Hematological risk

Drug-drug interaction between APs and Chloroquine/Hydroxychloroquine/Azithromycin

The primary interaction is the risk of QT prolongation and TdP because the three drugs for COVID-19 have “Known Risk of TdP” according to CredibleMeds®.

Recommended use of APs with these treatments is summarized in Table 2.

Table 2

Drug-drug interaction between: antipsychotics and chloroquine/hydroxychloroquine/azithromycin

(a)Potential increased exposure of Aps, (b) Additional interaction: phenothiazides/antimalarial (increased serum concentration of phenothiazines), (c) Additional interaction: Risk Hematological toxicity, (d) Paliperidone and Risperidone (P-glycoprotein/ABCB1 Substrates) and Azithromycin (P-glycoprotein/ABCB1 inhibitors), (e) Torsade de Pointes (TdP) Risk Categories by QTDrugs de CredibleMeds®: Known Risk of TdP (these drugs prolong the WT interval and are clearly associated with a known risk of TdP, even when taken as recommended), Possible Risk of TdP (these drugs can cause QT prolongation but currently lack evidence for risk of TdP when taken as recommended), Conditional Risk of TdP (these drugs are associated with TdP but only under certain conditions of their use (e.g., excessive dose, in patients with conditions such as hypokalemia, or when taken with interacting drugs) or by creating conditions that facilitate or induce TdP (e.g., by inhibiting metabolism of QT-prolonging drugs or by causing an electrolyte disturbance that induce TdP), Not classified (this drug has been reviewed but the evidence available at this time did not result in a decision for it to be placed in any of the four QT risk categories. This is not an indication that this drug is free of a risk of QT prolongation or Torsade de Pointes since it may not have been adequately tested for these risks in patients)

△There is not enough information to assign the antipsychotic to any of the previous risk rating categories; the recommendations reflect the most conservative approach. This recommendation to be taken with caution; ° No antipsychotics in this category

The summary information about the risk rating, severity, and patient management for each database is available in Supplement Tables 1, 2, and 3.

The recommended concomitant APs for use with these 3 COVID-19 drugs are asenapine, cariprazine, brexpiprazole, and lurasidone. Olanzapine may be used in combination with hydroxychloroquine and azithromycin, and risperidone with azithromycin. Olanzapine with chloroquine has different risk rating: green in Liverpool© Drug Interaction Group, yellow in Lexicomp® Drug Interactions, and orange in Micromedex® Solutions Drugs Interactions database; for that reason, it is not possible to reach an agreement according to the author’s consensus and the recommendations reflect the most conservative approach, and so it’s necessary to take it with caution.

Drug-drug interaction between APs and lopinavir/ritonavir

This coadministration involves CYP interactions and the risk of QT prolongation and TdP. Lopinavir and ritonavir have “Possible Risk of TdP” according to CredibleMeds®. Lopinavir is metabolized primarily by hepatic CYP3A4 isoenzymes. Ritonavir inhibit CYP2D6 in vitro but to a lesser extent than CYP3A4, and numerous pharmacokinetics studies suggested that ritonavir is a CYP 3A, 1A2, 2B6, 2C9, 2C19, and glucuronidation inducer. And also, ritonavir is an inducer and inhibitor of p-glycoprotein. The coadministration of lopinavir/ritonavir helps to stave off lopinavir’s biotransformation and increased plasma levels of active antiviral drug (thanks to minimize the first pass metabolism). Due to this co-treatment between lopinavir and ritonavir, concomitant therapy with other medications which are CYP3A4 substrate can lead to increased concentrations of these drugs. Consequently, the dose of CY3A4 substrates should be administered with caution when given in combination with lopinavir/ritonavir. And the induction effects of ritonavir on enzymes (CYP 3A, 1A2, 2B6, 2C9, 2C19, and diphosphate-glucuronosyltransferase) may result in lowered plasma concentrations and decrease of efficacy of the co-administered medicinal products (respective substrate), or may increase the concentrations of the active or toxic metabolite (in the case of prodrugs) (Cao et al. 2020; Foisy et al. 2008; Kim 2002; Mansuri et al. 2020).

Table 3 summarizes the recommended uses of APs with lopinavir/ritonavir. There are no APs with little to no evidence of clinically significant interaction expected. We recommend olanzapine, with caution and monitoring patients for reduced clinical effect (ritonavir induction of CYP1A2), and risperidone, monitoring for increased AP effects and the risk of QT prolongation and/or TdP.

Table 3

Drug-drug interaction between antipsychotics and lopinavir/ritonavir

(1) Avoid products containing alcohol (LOP/RIT) in patients treated with methotrimeprazine

♥♥ QT-Prolonging agents in 2 or more database, ♥ QT-Prolonging agents in 1 database. ❍: No database reports additive effects on QT-interval prolongation

↑/↓ Cytochrome P450 interaction (or UGT1A4 or P-glycoprotein/ABCB1 when correspond). Antipsychotic levels may increase/decreased and dose adjustment may be necessary

*Since ritonavir should be considered as CYP450 pan-inducer some of the information listed in this table, which has been attained from the reported data base, may differ if a more thorough and pertinent analysis of the literature on specific ritonavir-AP DDIs would be performed

Information about risk ratings, severity, and patient management in each database is summarized in Supplement Table 4.

Drug-drug interaction between APs and remdesivir

Lexicomp® Drug Interactions and Liverpool© Drug Interaction Group report that there are no significant risks. Remdesivir is not included in the Micromedex® Solutions Drugs Interactions database.

Drug-drug interaction between APs and favipiravir

Favipiravir are not included in the Micromedex® Solutions Drugs Interactions database. Lexicomp® Drug Interactions reports no significant risks and Liverpool© Drug Interaction Group shows yellow risk with chlorpromazine and quetiapine. Favipiravir is metabolized by aldehyde oxidase and quetiapine and chlorpromazine are known to inhibit this enzyme in vitro. However, the clinical relevance of aldehyde oxidase inhibition remains to be established. The yellow zone recommendations reflect the most conservative approach.

Drug-drug interaction between APs and tocilizumab

Micromedex® Solutions Drug Interactions presents no drug-drug interaction, and although the Liverpool© Drug Interaction Group reports risk of hematological toxicity with clozapine, it does not present evidence of clinically significant risk with the rest of antipsychotics. However, according to Lexicomp® Drug Interactions, tocilizumab may decrease the serum concentration of CYP3A4 substrates like aripiprazole, brexpiprazole, cariprazine, haloperidol, lurasidone, and quetiapine.

The information on risk rating, severity, and patient management for each database is summarized in Supplement Table 5.

The authors’ consensus recommendation (see Table 1) is that brexpiprazole, cariprazine, and lurasidone be used with caution. This is the most conservative approach, because they are not included in the Liverpool© database, and therefore, agreement is not possible.

Drug-drug interaction between APs and baricinitib

Baricinitib is not included in the Liverpool© Drug Interaction Group and Micromedex® Solutions Drugs Interactions shows no drug-drug interaction with antipsychotics. The summary information about the risk rating, severity, and patient management for each database is available in eTable 6 in the Supplement.

All antipsychotics are recommended, but not clozapine because of hematological risk (risk rating in zone yellow).

Drug-drug interaction between APs and anakinra

Anakinra is not included in the Liverpool© Drug Interaction Group. Micromedex® Solutions Drugs Interactions and Lexicomp® Drug Interactions do not report any drug-drug interaction with antipsychotics.

Results of the systematic review

Only 7 case reports out of the 391 studies screened and assessed for eligibility were finally included in the systematic revision, after applying inclusion and exclusion criteria (Supplement eFig. 1). Data from all included studies are summarized in Table 4. Two case reports are considered highly probable drug interaction according to DIPS, one with lopinavir/ritonavir and quetiapine (with priapism as the clinical outcome), and with ritonavir/indinavir and risperidone (with acute dystonia and tremor exacerbation as the clinical outcome). There were no deaths among the 8 patients, but two fatal outcomes, one patient in coma (Risperidone plus Ritonavir) and 2 others with neuroleptic malignant syndrome (ritonavir plus aripiprazole, and ritonavir plus risperidone); however, all of them remitted.

Table 4

Characteristics of the included studies involving patients with drug-drug interactions

Author/year	Title	Diagnosis	N	Treatment	Type of interaction	Clinical outcome	Patient management	Drug Interaction probability scale (DIPS)
Whiskey et al. 2018 (Whiskey et al. 2018)	Clozapine, HIV and neutropenia: a case report	Schizophrenia and HIV	1	CLZ 450 mg/day RIT 100 mg/day VAL 500 mg/day LMV and ZDV (not dose data)	Interaction CYP 3A4, CYP 2D6, CYP 1A2 and CYP 2C19	Neutropenia attributable to the action and/or interaction of drugs. Unable to conclude whether due to the study variable (CLZ and RIT)	Evaluated the possibility of using GCSF with CLZ VAL removal Changed antiretrovirals (Truvada and darunavir) and kept RIT	Possible
Geraci et al. 2010 (Geraci et al. 2010)	Antipsychotic-induced priapism in an HIV patient: a cytochrome P450-mediated drug interaction	HIV	1	LPV 200 mg/RIT 50 mg/day QUE 300 mg/day	Interaction CYP 2D6 and CYP 3A4	Priapism Increased levels of psychotropic drugs	Anesthetized locally with 1% lidocaine and epinephrine and irrigated with dilute ephedrine and saline	Highly probable
Aung et al. 2010 (Aung et al. 2010)	Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir	HIV and anxiety-depressive syndrome	1	ARI 50 mg/day RIT 100 mg/day	Interaction CYP 2D6 and CYP 3A4	NMS Increased levels of antipsychotic drugs	Disruption of the neuroleptics Intensive fluid therapy administration	Probable
Pollack et al. 2009 (Pollack et al. 2009)	Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients	First patient: HIV + BD Second patient: HIV, anxiety disorder and substance abuse disorder	2	QUE400/day RIT100/day	Interaction CYP 3A4	Patient 1: Increase of 22 kg in 6 months. Glucose level: 259 mg/dL Patient 2: delirium	Patient 1: RIT was replaced with abacavir and the patient lost 5 kilograms per month and his serum glucose level had normalized Patient 2: QUE stopped and resolution of mental status	Probable
Jover et al. 2002 (Jover et al. 2002)	Reversible coma caused by risperidone-ritonavir interaction	HIV and manic episode	1	RIS 3 mg/day RIT200 mg/day	Interaction CYP 2D6 and CYP 3A4	Coma	APs stopped 24 h later, neurological status returned to baseline and manic symptoms gradually reappeared	Probable
Kelly et al. 2002 (Kelly et al. 2002)	Extrapyramidal symptoms with ritonavir/indinavir plus risperidone	HIV and Tourette’s syndrome	1	RIS 4 mg/day RIT 400 mg /day	Interaction of both drugs via CYP 2D6	Acute dystonia and tremor exacerbation	APs stopped 3 days later the symptoms improved significantly	Highly probable
Lee et al. 2000 (Lee et al. 2000)	Neuroleptic malignant syndrome associated with use of risperidone, ritonavir, and indinavir: a case report	HIV and acute psychotic episode	1	RIS 1.5 mg/day RIT 400 mg/day	Interaction Track CYP 2D6 and CYP 3A4	NMS	RIS and RIT were discontinued Dantrolene and bromocriptine were started. Clinical remission 2 weeks later	Probable

ARI aripiprazole; BD bipolar disorder; CLZ clozapine; GCSF granulocyte stimulating factor; LMV lamivudine; LPV lopinavir; NMS neuroleptic malignant syndrome; QUE quetiapine; RIT ritonavir; RIS risperidone; VAL valproic acid; ZDV zidovudine

There was no study or case report about QT prolongation and/or TdP between the drugs of our study.

Discussion

According to the DDIs databases and our systematic review, remdesivir, baricinitib, and anakinra may be concomitantly used with antipsychotics by clinicians for managing delirium, agitation, or behavioral problems in COVID-19 patients with no risk of drug-drug interaction (except for hematological risk with clozapine and baricinitib reported only in one database). Favipiravir only needs caution with chlorpromazine and quetiapine (reported only in one database).

Tocilizumab is quite safe for use in combination with antipsychotics; however, care should be taken with aripiprazole, brexpiprazole, cariprazine, haloperidol, lurasidone, and quetiapine, because of decreased exposure of APs, and with clozapine because of hematological risk. Tocilizumab binds to and inhibits the proinflammatory cytokine interleukin-6 (IL-6), and IL-6 decreased CYP3A4 mRNA by over 90% (Aitken and Morgan 2007). Tocilizumab may restore CYP3A4 activity and thus increase CYP3A4 substrate metabolism. This effect may persist for several weeks following discontinuation of therapy due to the long half-life of tocilizumab.

The COVID-19 treatments with the most risk for coadministration with antipsychotics are chloroquine, hydroxychloroquine, azithromycin, and lopinavir/ritonavir.

Most of the DDIs databases point out the increased risk of prolonged QT interval with coadministration of chloroquine, hydroxychloroquine, and azithromycin with antipsychotics. Nevertheless (White 2007), the cardiotoxicity of antimalarial drugs, with the exception of quinidine and halofantrine, which produce clinically significant prolongation of ventricular repolarization, remains to be confirmed (Haeusler et al. 2018; White 2007). In the present COVID scenario, Borba et al. (Borba et al. 2020) do not recommend the highest chloroquine dosage for patients critically ill with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir. Risk of prolonged QTc (over 500 ms) was higher in patients receiving high doses (600 mg twice daily for 10 days) than a low-dosage group (450 mg twice on Day 1 followed by once daily for four days), 18.9% versus 11.1%, respectively. It is worth mentioning that all patients were also receiving azithromycin, and nearly all were receiving oseltamivir (both also prolong QT interval) (Fihn et al. 2020). Although treatment with hydroxychloroquine, azithromycin, or both was not compared with either treatment, in 1438 hospitalized patients with COVID-19, it was not significantly associated with differences in in-hospital mortality (Rosenberg et al. 2020). In addition, grading antipsychotics by torsadogenic risk is not a simple issue, and attributable risk varies depending on the source (Leucht et al. 2013; Raschi et al. 2013).

Our work also suggests that the coadministration of protease inhibitors, such as lopinavir/ritonavir, with APs should be cataloged as the most problematic combination, because of the CYP DDIs (Ernest et al. 2005) and the risk of QT prolongation and/or TdP. Coadministration of ritonavir and medicinal products primarily metabolized by CYP3A4 may result in increased plasma concentrations. Since ritonavir should be considered a pan-inducer of CYP450 (ritonavir induces cytochrome P450 enzymes 3A, 1A2, 2B6, 2C9, and 2C19, as well as glucuronyl transferase), the management of induction interactions is often unclear. When the substrate drug has a narrow therapeutic window or when the consequences of treatment failure are severe, alternative agents should be considered. Patients should be closely monitored for decreased efficacy of substrate medications when ritonavir is initiated. And, if ritonavir is stopped, lower doses of substrate medications should be considered and patients should be monitored very closely for toxicity. It is important to indicate that ritonavir has mixed effect, induction and inhibition on CYP3A (although inhibitory interactions are more prevalent); it has been proposed as an autoinducer (Hsu et al. 1997). The extent of induction was greater at higher doses, minimal al the lowest dose, and stabilized after 2 weeks. The simultaneous inhibition and induction effect requires further study with other CYP3A substrates, and caution in the study design (dose of ritonavir, duration of study, other co-administered protease inhibitor) when interpreting the results (Foisy et al. 2008). Clinicians should take this into account and be extremely cautious with patients.

Although none of the APs seems to be recommended for used in combination with lopinavir/ritonavir, olanzapine might be considered as the safest option according to DDIs databases and also because none of the case report describing DDI has been reported. Ritonavir decreases systemic exposure to olanzapine through the induction of both CYP1A2 and UGT. Thus, patients on concomitant olanzapine and ritonavir may require higher doses (up to 50% more) of olanzapine to achieve similar plasma concentrations (Meemken et al. 2015; Penzak et al. 2002).

Strengths and limitations

The use of drug interaction databases can be a useful clinical tool, but the lack of agreement between them limits their use (Abarca et al. 2004; Chao and Maibach 2005; Fulda et al. 2000; Monteith and Glenn 2019; Vitry 2007). Our study reviewed DDIs in three databases which fulfill quality criteria (Patel and Beckett 2016; Rodríguez-Terol et al. 2009), and a systematic review of the literature was also dome in search of possible clinical outcomes of these DDIs.

The main treatments used internationally for the treatment of COVID-19 were included, as well as most antipsychotics.

As limitations of our study, it should be noted that no studies were found beyond clinical cases which examined clinical results of the interaction between the drugs studied, so this information could not be presented. Another limitation to be acknowledged is the fact that ritonavir is CYP450 pan-inducer, and therefore, some inconsistencies between the interaction profiles described in the current datasets utilized in our manuscript and those described in particular scientific reports exploring the potential interaction between ritonavir and specific antipsychotics might emerge.

Conclusions

In conclusion, the growing use of antipsychotics in COVID-19 patients calls on the urges development evidence-based guidelines that can help clinicians decide on the safest treatment combination and the level of monitoring that would be warranted for each particular patient. Clinicians prescribing antipsychotics should be aware of the likely risk of drug-drug interaction with COVID-19 medication and may benefit from taking into account present recommendations of use to preserve patient safety. The main interactions between COVID-19 drugs and antipsychotics are the risk of QT prolongation and/or TdP, and CYP interactions.

(DOCX 80 kb)